Vaccine manufacturing firm GreenSignal Bio Pharma has fixed the price band at Rs 76-80 per equity for its initial public offer (IPO) through which it plans to raise around Rs 112 crore.
The company is entering the capital market with its initial public offering of 1,45,79,560 equity shares of face value of Rs 10 each through an offer for sale by promoter selling shareholders P Sundaraparipooranan and P Murali, promoter's group selling shareholder Mallika Murali and public selling shareholders R Srinivasan and Avon Cycles Ltd.
The 100 per cent book building issue will open on November 9 and closes on November 11.
The equity shares are proposed to be listed on BSE and NSE.
The firm is engaged in manufacturing of BCG vaccine, given for protection against tuberculosis, mainly severe forms of childhood tuberculosis.
The global demand for BCG vaccines is estimated at approximately 280 million doses annually, with the highest requirement coming from India. The total shortfall for BCG vaccination is estimated at nearly 30 million doses annually, GSBPL Managing Director P Murali told reporters here.
GSBPL is one of the four companies worldwide who have been WHO-prequalified to supply the BCG vaccine to UNICEF.
At present the company produces two products namely BCG vaccine for immunisation against Tuberculosis and BCG-ONCO for Immunotherapy (Freeze Dried) BP for the treatment of urinary bladder Carcinoma.
The company's major domestic client is Ministry of Health & Family Welfare and overseas client is UNICEF.
The company has a firm order of 84 lakhs vials to be executed in the next two years. GSBPL also exports products to 17 countries either directly through UNICEF or indirectly, through supply, distribution and other arrangements, Murali said.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)